Table 2.

Evaluating the sensitivity of released circulating tumor cells (CTCs) to chemotherapeutic drugs.

		Number of spheroids
Patient no	CTC counts	Sorafenib (-)	Sorafenib (+)	Inhibition rate, %
2	32	24	18	25.0
6	24	19	15	21.1
10	22	15	11	26.7
18	42	27	21	22.2
22	25	20	16	20.0
		Number of spheroids
Patient no.	CTC counts	Oxaliplatin (-)	Inhibition rate, %Oxaliplatin (+)
23	21	17	11	35.3
24	37	32	29	9.4
31	21	16	13	18.8
32	22	19	16	15.8
36	21	17	15	11.8